Vaxcyte Q2 net loss widens on higher expenses
PCVX•Outlook
- Vaxcyte expects OPUS-1 Phase 3 adult trial topline data in Q4 2026
- Company expects OPUS-2 and OPUS-3 Phase 3 results in H1 2027
- Vaxcyte expects VAX-31 infant Phase 2 study data by end of H1 2027
Overview
- U.S. vaccine developer's Q2 net loss widened yr/yr but beat analyst expectations
- Operating expenses rose due to increased R&D and manufacturing costs for PCV programs
- Company ended Q2 with $2.5 bln in cash, supporting ongoing clinical trials
Key Details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Net Loss | Beat | $284.3 mln | $298.28 mln (8 Analysts) |
| Q2 Operating Expenses | $302.78 mln |
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the biotechnology & medical research peer group is "buy"
- Wall Street's median 12-month price target for Vaxcyte, Inc. is $110.00, about 101.1% above its August 4 closing price of $54.69
Result Drivers
Related News
Grab Chief Org Capability Officer Ong Chin Yin sells 38,000 shares for $137,263.6
GRAB•
DHT Q2 FY26 profit rises 253.9% to USD 198.3 million; revenue more than doubles to USD 284.8 million
DHT•
